ABION Inc. (KOSDAQ:203400)

Market Cap	279.31B +44.5%
Revenue (ttm)	1.03B +24.4%
Net Income	-28.06B
EPS	-553.66
Shares Out	90.10M
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	464,867
Average Volume	1,292,427
Open	2,865.00
Previous Close	2,875.00
Day's Range	2,805.00 - 2,930.00
52-Week Range	1,911.11 - 7,277.78
Beta	1.06
RSI	47.97
Earnings Date	Mar 20, 2026

About ABION

ABION Inc. operates as a pharmaceutical biotech Company in South Korea and internationally. The company develops anticancer therapeutic drugs, such as ABN401, a tyrosine kinase inhibitor that is in Phase II clinical trials for treating non-small cell lung cancer, as well as in Phase I clinical trial for breast cancer; ABN501, a human monoclonal antibody that targets claudin 3 for treating solid cancers; ABN201, an antibody cytokine fusion protein to treat solid cancers; and ABN101, a dry powder inhaler as a prophylactic treatment for various re...

• Industry: Biological Products, Except Diagnostic Substances
• Founded: 2007
• Country: South Korea
• Stock Exchange: KOSDAQ
• Ticker Symbol: 203400

Financial Performance

In 2024, ABION's revenue was 759.68 million, a decrease of -40.38% compared to the previous year's 1.27 billion. Losses were -43.38 billion, 48.5% more than in 2023.